These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 16566369)
1. [Novel treatment for severe sepsis: recombinant human protein C (RHAPC)]. Uszyiński W; Uszyński M; Lisiecki A Ginekol Pol; 2005 Nov; 76(11):913-20. PubMed ID: 16566369 [TBL] [Abstract][Full Text] [Related]
2. [Severe sepsis treated with activated protein C]. Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807 [TBL] [Abstract][Full Text] [Related]
3. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study. de Pont AC; Bakhtiari K; Hutten BA; de Jonge E; Vroom MB; Meijers JC; Büller HR; Levi M Crit Care; 2005 Oct; 9(5):R490-7. PubMed ID: 16277710 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human activated protein C for severe sepsis in neonates. Kylat RI; Ohlsson A Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD005385. PubMed ID: 22513930 [TBL] [Abstract][Full Text] [Related]
5. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Bernard GR; Ely EW; Wright TJ; Fraiz J; Stasek JE; Russell JA; Mayers I; Rosenfeld BA; Morris PE; Yan SB; Helterbrand JD Crit Care Med; 2001 Nov; 29(11):2051-9. PubMed ID: 11700394 [TBL] [Abstract][Full Text] [Related]
6. Activated protein C (Xigris) treatment in sepsis: a drug in trouble. Gårdlund B Acta Anaesthesiol Scand; 2006 Sep; 50(8):907-10. PubMed ID: 16923083 [TBL] [Abstract][Full Text] [Related]
7. Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma. Dahabreh Z; Dimitriou R; Chalidis B; Giannoudis PV Expert Opin Drug Saf; 2006 Jan; 5(1):67-82. PubMed ID: 16370957 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Derhaschnig U; Reiter R; Knöbl P; Baumgartner M; Keen P; Jilma B Blood; 2003 Sep; 102(6):2093-8. PubMed ID: 12750166 [TBL] [Abstract][Full Text] [Related]
10. Recombinant human activated protein C in severe sepsis. Mann HJ Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S19-23. PubMed ID: 11885409 [TBL] [Abstract][Full Text] [Related]
11. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Maybauer MO; Maybauer DM; Fraser JF; Traber LD; Westphal M; Enkhbaatar P; Cox RA; Huda R; Hawkins HK; Morita N; Murakami K; Mizutani A; Herndon DN; Traber DL Crit Care Med; 2006 Sep; 34(9):2432-8. PubMed ID: 16810106 [TBL] [Abstract][Full Text] [Related]
12. Recombinant human activated protein C: current insights into its mechanism of action. Levi M; van der Poll T Crit Care; 2007; 11 Suppl 5(Suppl 5):S3. PubMed ID: 18269690 [TBL] [Abstract][Full Text] [Related]
13. Recombinant human-activated protein C (rhAPC) in childhood sepsis. Frassica JJ; Vinagre YM; Maas B J Intensive Care Med; 2004; 19(1):56-7. PubMed ID: 15035756 [No Abstract] [Full Text] [Related]
14. Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Brueckmann M; Hoffmann U; Dvortsak E; Lang S; Kaden JJ; Borggrefe M; Haase KK Inflamm Res; 2004 Oct; 53(10):528-33. PubMed ID: 15597147 [TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure. Brueckmann M; Wizenmann J; Hoffmann U; Seeger M; Bewig B Thromb Res; 2003 Mar; 109(5-6):259-63. PubMed ID: 12818248 [TBL] [Abstract][Full Text] [Related]
16. Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C. Ullery B; Pieracci FM; Hydo LJ; Eachempati SR; Barie PS Surg Infect (Larchmt); 2008 Jun; 9(3):389-94. PubMed ID: 18570580 [TBL] [Abstract][Full Text] [Related]
17. The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Pérez-Casal M; Thompson V; Downey C; Welters I; Wyncoll D; Thachil J; Toh CH Crit Care; 2011 Aug; 15(4):R195. PubMed ID: 21834973 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Barie PS; Hydo LJ; Shou J; Eachempati SR Surg Infect (Larchmt); 2011 Dec; 12(6):443-9. PubMed ID: 22185191 [TBL] [Abstract][Full Text] [Related]
19. Natural anticoagulant inhibitors: activated Protein C. Aird WC Best Pract Res Clin Haematol; 2004 Mar; 17(1):161-82. PubMed ID: 15171965 [TBL] [Abstract][Full Text] [Related]
20. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis]. Spies C; Otter H; Zuckermann-Becker H; Kox WJ Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]